Pain related to cancer treatments and diagnostic procedures: A no man's land?

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1097-1106

  Ripamonti, Carla I ^a   Bossi, P ^a   Santini, D ^b   Fallon, M ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; Diagnostic procedures; Oncological treatments; Pain management

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYTARABINE; DOXEPIN; DOXORUBICIN; ETOPOSIDE; FENTANYL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LOCAL ANESTHETIC AGENT; METHOTREXATE; MORPHINE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; PYRIDOXINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; STEROID; SUNITINIB; TAMOXIFEN; UNINDEXED DRUG; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ARTHRALGIA; ARTIFICIAL EMBOLISM; AUTONOMIC PAIN; BLOOD SAMPLING; BONE MARROW BIOPSY; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER THERAPY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; EDEMA; ENDOSCOPY; EYE PAIN; FATIGUE; FEVER; FLU LIKE SYNDROME; FRACTURE; HAND FOOT SYNDROME; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; IATROGENIC PAIN; JAW OSTEONECROSIS; LUMBAR PUNCTURE; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROPATHIC PAIN; ONCOLOGY; OSTEOPENIA; OSTEOPOROSIS; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PLEURODESIS; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SOMATIC PAIN; SUPRAPUBIC CATHETERIZATION; THORACOCENTESIS; TRANSTHORACIC BIOPSY; VISCERAL PAIN; VOMITING; ANALGESIA; COMPLICATION; NEOPLASMS; PROCEDURES;

HUMANS; NEOPLASMS; PAIN; PAIN MANAGEMENT;

EID: 84903909010     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu011     Document Type: Review

References (136)

1. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg 2007; 105: 205-221.
2. Republic of Italy: Linee Guida Ospedale Senza Dolore. Conferenza Permanente per i rapporti tra lo Stato, le regioni e le Provincie Autonome di Trento e Bolzano. Gazzetta Ufficiale della Repubblica Italiana, Serie Generale no. 149; 29/06/2001.
3. Republic of Italy: DL 15 marzo 2010, n. 38 Disposizioni per garantire l'accesso alle cure palliative e alla terapia del dolore. Gazzetta Ufficiale, Serie Generale no.65; 19/03/2010.
4. World Health Organization. Cancer Pain Relief, 2nd edition. Geneva: World Health Organization, 1996.
5. National Comprehensive Cancer Network (NCCN). Clinical Practice Guideline in Oncology. Adult Cancer Pain VI. Washington 2009.
6. Scottish Intercollegiate Guidelines Network Control of pain in adults with cancer. A National Clinical Guideline. SIGN-Scottish Intercollegiate Guidelines Network, Edinburgh 2008.
7. Caraceni A, Hanks G, Kaasa S et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: 58-68.
8. Ripamonti CI, Santini D, Maranzano E et al. Management of cancer pain: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii139-54.
9. Sun V, Borneman T, Piper B et al. Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv 2008; 2: 65-71.
10. Burton AW, Fanciullo GJ, Beasley RD et al. Chronic pain in cancer survivor: a new frontier. Pain Med 2007; 8: 189-198.
11. Deandrea S, Montanari M, Moja L et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19: 1985-1991.
12. Costantini M, Ripamonti C, Beccaro M et al. Prevalence, distress, management and relief of pain during the last three months of cancer patients' life. Results of an Italian mortality follow-back survey. Ann Oncol 2009; 20: 729-735.
13. Breivik H, Cherny N, Collett F et al. Cancer-related pain: a pan European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009; 20: 1420-1433.
14. Morselli M, Bandieri E, Zanin R et al. Pain and emotional distress in leukaemia patients at diagnosis. Leuk Res 2009; 34: e67-e68.
15. Apolone G, Corli O, Caraceni A et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 2009; 100: 1566-1574.
16. Ripamonti CI, Sichetti D, Fanizza C et al. on the behalf of ECAD_O Working Group. Is pain reporting to health care professionals age-related? A cross sectional multicenter study in a hospital setting. Expert Opin Pharmacother. 2013; 14: 2011-7.
17. Katalinic D, Anic B, Stern-Padovan R et al. Low back pain as the presenting sign in a patients with primary ectradural melanoma of the thoracic spine. A metastatic disease 17 years after complete surgical resection. World J Surg Oncol 2011; 9: 150-155.
18. Smit M, Balm AJ, Hilgers FJ et al. Pain as sign of recurrent disease in head and neck squamous cell carcinoma. Head Neck 2001; 23: 372-375.
19. Van den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-1449.
20. Portenoy RK, Thaler HT, Kornblith AB et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994; 3: 183-189.
21. Vuorinen E. Pain as an early symptom in cancer. Clin J Pain 1993; 9: 272-278.
22. Sichetti D, Bandieri E, Romero M et al. for ECAD_O Working Group. Impact of setting of care on pain management in patients with cancer: a multicentre crosssectional study. Ann Oncol 2010; 21: 2088-2093.
23. Association Together Against pain. Towards A Pain-Free Hospitals. http://www. againstpain.org/en/vershopsd.php (25 August 2013, date last accessed).
24. Acute Pain Management: Operative or Medical Procedures and Trauma. Clinical Practice Guideline Number 1. Rockville, MD: US Dept of Health and Human Services, Agency for Health Care Policy and Research; AHCPR publication 92-0032, 1992.
25. Grossman SA, Sheidler VR, Swedeen K et al. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 1991; 6: 53-57.
26. Forrest M, Hermann G, Andersen B. Assessment of pain: a comparison between patients and doctors. Acta Anaesthesiol Scand 1989; 33: 255-256.
27. Woolf CJ, Chong MS. Preemptive analgesia-treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993; 77: 362-379.
28. Vanhelleputte P, Nijs K, Delforge M et al. Pain during bone marrow aspiration: prevalence and prevention. J Pain Symptom Manage 2003; 26: 860-866.
29. Lidén Y, Landgren O, Arnér S. Procedure-related pain among adult patients with hematologic malignancies. Acta Anaesthesiol Scand 2009; 53: 354-363.
30. Talamo G, Liao J, Joudeh J et al. Perceived levels of pain associated with bone marrow aspirates and biopsies. J Support Oncol 2012; 10: 166-170.
31. Hjortholm N, Jaddini E, Hałaburda K et al. Strategies of pain reduction during the bone marrow biopsy. Ann Hematol 2013; 92: 145-149.
32. Kuivalainen AM, Niemi-Murola L, Widenius T et al. Comparison of articaine and lidocaine for infiltration anaesthesia in patients undergoing bone marrow aspiration and biopsy. Eur J Pain 2010; 14: 160-163.
33. Mainwaring CJ, Wong C, Lush RJ et al. The role of midazolam-induced sedation in bone marrow aspiration/trephine biopsies. Clin Lab Haematol 1996; 18: 285-288.
34. Giannoutsos I, Grech H, Maboreke T et al. Performing bone marrow biopsies with or without sedation: a comparison. Clin Lab Haematol 2004; 26: 201-204.
35. Park SH, Bang SM, Nam E et al. A randomized double-blind placebo-controlled study of low-dose intravenous lorazepam to reduce procedural pain during bone marrow aspiration and biopsy. Pain Med 2008; 9: 249-252.
36. Steedman B, Watson J, Ali S et al. Inhaled nitrous oxide (Entonox) as a short acting sedative during bone marrow examination. Clin Lab Haematol 2006; 28: 321-324.
37. Gudgin EJ, Besser MW, Craig JI. Entonox as a sedative for bone marrow aspiration and biopsy. Int J Lab Hematol 2008; 30: 65-67.
38. Kuivalainen AM, Ebeling F, Rosenberg PH. Pre-medication with sublingual fentanyl did not relieve pain associated with bone marrow aspiration and biopsy: A randomized feasibility trial. Eur J Pain 2013.
39. Bezov D, Ashina S, Lipton R. Post-dural puncture headache: part II-prevention, management, and prognosis. Headache 2010; 50: 1482-1498.
40. Vilming ST, Kloster R. The time course of post-lumbar puncture headache. Cephalalgia 1998; 18: 97-100.
41. Turnbull DK, Shepherd DB. Post-dural puncture headache: pathogenesis, prevention and treatment. Br J Anaesth 2003; 91: 718-729.
42. Clements R, Aideyan OU, Griffiths GJ et al. Side effects and patient acceptability of transrectal biopsy of the prostate. Clin Radiol 1993; 47: 125-126.
43. Nash PA, Bruce JE, Indudhara R et al. Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 1996;155 (2): 607-609.
44. Hirsh I, Kaploun A, Faris G et al. Tramadol improves patients' tolerance of transrectal ultrasound-guided prostate biopsy. Urology 2007; 69: 491-494.
45. Ozok HU, Sagnak L, Ates MA et al. The efficiency of a sedative or analgesic supplement to periprostatic nerve blockage for pain control during transrectal ultrasound-guided prostate biopsy-a prospective, randomized, controlled, double blind study. Arch Med Sci 2010; 6: 787-792.
46. Brennan PA, Mackenzie N, Oeppen RS et al. Prospective randomized clinical trial of the effect of needle size on pain, sample adequacy and accuracy in head and neck fine-needle aspiration cytology. Head Neck 2007; 29: 919-922.
47. Gursoy A, Ertugrul DT, Sahin M et al. The analgesic efficacy of lidocaine/prilocaine (EMLA) cream during fine-needle aspiration biopsy of thyroid nodules. Clin Endocrinol (Oxf) 2007; 66: 691-694.
48. Daltrey IR, Kissin MW. Randomized clinical trial of the effect of needle gauge and local anaesthetic on the pain of breast fine-needle aspiration cytology. Br J Surg 2000; 87: 777-779.
49. Radowsky JS, Baines L, Howard RS et al. Pain ratings by patients and their providers of radionucleotide injection for breast cancer lymphatic mapping. Pain Med 2012; 13: 670-676.
50. Eisenberg E, Konopniki M, Veitsman E et al. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analg 2003; 96: 1392-1396.
51. Senore C, Ederle A, Fantin A et al. Acceptability and side-effects of colonoscopy and sigmoidoscopy in a screening setting. J Med Screen 2011; 18: 128-134.
52. Zubarik R, Ganguly E, Benway D et al. Procedure-related abdominal discomfort in patients undergoing colorectal cancer screening: a comparison of colonoscopy and flexible sigmoidoscopy. Am J Gastroenterol 2002; 97: 3056-3061.
53. Romero FR, Romero AW, Brenny Filho T et al. Patients' perceptions of pain and discomfort during digital rectal exam for prostate cancer screening. Arch Esp Urol 2008; 61: 850-854.
54. Puntillo KA, White C, Morris AB et al. Patients' perceptions and responses to procedural pain: results from Thunder Project II. Am J Crit Care 2001; 10: 238-251.
55. Puntillo KA, Wild LR, Morris AB et al. Practices and predictors of analgesic interventions for adults undergoing painful procedures. Am J Crit Care 2002; 11: 415-429.
56. Faigeles B, Howie-Esquivel J, Miaskowski C et al. Predictors and use of nonpharmacologic interventions for procedural pain associated with turning among hospitalized adults. Pain Manag Nurs 2013; 14: 85-93.
57. Sawyer J, Febbraro S, Masud S et al. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. Br J Anaesth 2009; 102: 210-215.
58. Culp WC, Jr, Yousaf M, Lowry B et al. Pain and efficacy of local anesthetics for central venous access. Local Reg Anesth 2008; 1: 11-15.
59. Pucino F, Danielson BD, Carlson JD et al. Patient tolerance to intravenous potassium chloride with and without lidocaine. Drug Intell Clin Pharm 1988; 22: 676-679.
60. Sauerland C, Engelking C, Wickham R et al. Vesicant extravasation part I: mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006; 33: 1134-1141.
61. Wickham R, Engelking C, Sauerland C et al. Vesicant extravasation part II: evidence-based management and continuing controversies. Oncol Nurs Forum 2006; 33: 1143-1150.
62. Vogelzang N. Adriamycin flare: a skin reaction resembling extravasation. Cancer Treat Rep 1979; 63: 2067-2069.
63. Curran CF, Luce JK, Page JA. Doxorubicin-associated flare-reactions. Oncol Nurs Forum 1990; 17: 387-389.
64. Peterson DE, Lalla RV. Oral mucositis: the new paradigms. Curr Opin Oncol 2010; 22: 318-322.
65. Loprinzi CL, Maddocks-Christianson K, Wolf SL et al. The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 2007; 13: 399-403.
66. Garrison JA, McCune JS, Livingston RB et al. Myalgias and arthralgias associated with Paclitaxel. Oncology (Williston Park) 2003; 17: 271-277.
67. Loprinzi CL, Reeves BN, Dakhil SR et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011; 29: 1472-1478.
68. Markman M, Kennedy A, Webster K et al. Use of lose-dose oral prednisolone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol 1999; 72: 100-101.
69. Insinga RP, Itzler RF, Pellisser JM et al. The incidence of herpes zoster in a United Sates administrative database. J Gen Intern Med 2005; 20: 748-753.
70. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol 1986; 20: 651-664.
71. Rusthoven JJ, Ahlgren P, Elhakim T et al. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med 1988; 148: 1561-1566.
72. Galer BS, Portenoy RK. Acute herpetic and postherpetic neuralgia: clinical features and management. Mt Sinai J Med 1991; 58: 257-266.
73. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12: 131-141.
74. Alberts DS, Farcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54(Suppl 4): 30-35.
75. Vukelja SJ, Baker WJ, Burris HAD et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85: 1432-1433.
76. Bellmunt J, Navarro M, Hidalgo R et al. Palmar-plantar erythrodysestheisa syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. Tumori 1988; 74: 329-331.
77. Fabian CJ, Molina R, Slavik M et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57-63.
78. Long TD, Twillman RK, Cathers-Schiffman TA et al. Treatment of vinorelbineassociated tumor pain. Am J Clin Oncol 2001; 24: 414-415.
79. Tralongo P, Di Mari A, Agueli R et al. Oral vinorelbine may not induce acute pain at the tumor site. J Pain Symptom Manage 2006; 32: 197-199.
80. Tanvetyanon T, StiffPJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17: 897-907.
81. Reid IR, Gamble GD, Mesenbrink P et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010; 95: 4380-4387.
82. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
83. Rosen LD, Gordon DH, Dugan W, Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36-43.
84. Karapetis CS, Kotasek D, Norman JE et al. Acute gait disturbance associated with pamidronate infusion. Aust N Z J Med 1997; 27: 719-720.
85. Wark J, Recknor C, Ryabitseva O et al. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Bone 2000; 46(Suppl 1): S33.
86. Migliorati CA, Schubert MM, Peterson DE et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83-93.
87. Henry D, von Moos R, Vadhan-Raj S et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer Suppl 2009; 7: 12.
88. Saad F, Brown JE, Van Poznak C et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.
89. American Association of Oral and Maxillofacial Surgeons. Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw-2009 Update. http://www. aaoms.org/docs/position_papers/bronj_update.pdf.
90. Weitzman R, Sauter N, Eriksen EF et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients. Crit Rev Oncol Hematol 2007; 62: 148-152.
91. Ripamonti CI, Cislaghi E, Mariani L et al. Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Preliminary results of a phase I-II study. Oral Oncol 2011; 47: 185-190.
92. Ripamonti C, Maniezzo M, Pessi M et al. Efficacy and tolerability of medical ozone (O3) gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates. Preliminary data. Medical ozone gas insufflation in treating ONJ lesions. J Bone Oncol 2012; 1: 81-87.
93. Kubista E, Glaspy J, Holmes FA et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily pegfilgrastim in patients with breast cancer. Clin Breast Cancer 2003; 3: 391-398.
94. Heil G, Hoelzer D, Sanz MA et al. A randomized, double-blind, placebocontrolled, phase III study of figrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukaemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710-4718.
95. Kirshner JJ, Heckler CE, Janelsins MC et al. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base. J Clin Oncol 2012; 30: 1974-1979.
96. Kirshner J, Hickock J, Hofman M. Pegfilgrastim induced bone pain: incidence, risk factors, and management in a community practice. Comm Onc 2007; 4: 455-459.
97. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
98. Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-1051.
99. Lacouture ME, Maitland ML, Segaert S et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010; 18: 509-522.
100. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-812.
101. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009; 77: 257-271.
102. Sonis S, Treister N, Chawla S et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010; 116: 210-215.
103. Lacouture ME, Anadkat MJ, Bensadoun RJ et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19: 1079-1095.
104. Boers-Doets CB, Epstein JB, Raber-Durlacher JE et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17: 135-144.
105. Epstein JB, Wilkie DJ, Fischer DJ et al. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol 2009; 1: 26.
106. http://www.mascc.org/mucositis-guidelines (25 August 2013, date last accessed).
107. Ling IS, Larsson B. Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy. Support Care Cancer 2011; 19: 1343-1350.
108. Andreyev HJ, Vlavianos P, Blake P et al. Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist? Int J Radiat Oncol Biol Phys 2005; 62: 1464-1471.
109. Babb RR. Radiation proctitis: a review. Am J Gastroenterol 1996; 91: 1309-1311.
110. Chow E. Update on radiation treatment for cancer pain. Curr Opin Support Palliat Care 2007; 1: 11-15.
111. Hird A, Chow E, Zhang L et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three Canadian cancer centers. Int J Radiat Oncol Biol Phys 2009; 75: 193-197.
112. Hird A, Zhang L, Holt T et al. Dexamethasone for the prophylaxis of radiationinduced pain flare after palliative radiotherapy for symptomatic bone metastases: a phase II study. Clin Oncol (R Coll Radiol) 2009; 21: 329-335.
113. Kwekkeboom KL, Dendaas NR, Straub M et al. Patterns of pain and distress during high-dose-rate intracavity brachytherapy for cervical cancer. J Support Oncol 2009; 7: 108-114.
114. Smith MD, Todd JG, Symonds RP. Analgesia for pelvic brachytherapy. Br J Anaesth 2002; 88: 270-276.
115. Colella J, Scrofine S, Galli B et al. Prostate HDR radiation therapy: a comparative study evaluating the effectiveness of pain management with peripheral PCA versus PCEA. Urol Nurs 2006; 26: 57-61.
116. Janaki MG, Nirmala S, Kadam AR. Epidural analgesia during brachytherapy for cervical cancer patients. J Cancer Res Ther 2008; 4: 60-63.
117. Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and musculoskeletal complications in cancer survivors. Physician Medicine & Rehabilitation 2011; 3: 1041-1054.
118. Thorn JJ, Hansen HS, Specht L et al. Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. J Oral Maxillofac Surg 2000; 58: 1088-1093.
119. Dunlap NE, Cai J, Biedermann GB et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76: 796-801.
120. Forquer JA, Fakiris AJ, Timmerman RD et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009; 93: 408-413.
121. Gärtner R, Jensen MB, Nielsen J et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 2009; 302: 1985-1992.
122. Nunns D, Williamson K, Swaney L et al. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial carcinoma. Int J Gynecol Cancer 2000; 10: 233-238.
123. Pettersson N, Olsson C, Tucker SL et al. Urethral pain among prostate cancer survivors 1 to 14 years after radiation therapy. Int J Radiat Oncol Biol Phys 2013; 85: e29-e37.
124. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
125. Bryce J, Bauer M, Hadji P. Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormone- sensitive early breast cancer: a case study. Cancer Manage Res 2012; 4: 105-111.
126. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011; 13: 205.
127. Coleman RE, Bolten WW, Lansdown M et al. Aromatase inhibitor- induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008; 34: 275-282.
128. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005; 52: 2594-2598.
129. Coates AS, Cuzick J, Baum M et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
130. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007; 369: 559-570.
131. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in recent-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 95: 1262-1271.
132. Boccardo F, Rubagotti A, Guglielmini P et al. Switching to anastrozole versus continued tamoxifen treated of early breast cancer. Updated results of the Italian tamoxifene anastrozole (ITA) trial. Ann Oncol 2006; 17(Suppl 7): vii10-vii14.
133. Moxley G. Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clin Breast Cancer 2010; 10: 144-147.
134. Henry NL, Giles JT, Ang D et al. Prospective characterization of muscoloskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008; 111: 365-372.
135. Morales L, Pans S, Paridaens R et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associayed tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007; 104: 87-91.
136. Henry NL, Banerjee M, Wicha M et al. Pilot study of duloxetin for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 2011; 117: 5469-5475.